Competition intensifies in already crowded multiple sclerosis space
05/09/19 -"Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. While this would dent the sales of Aubagio, Novartis’ ..."
Pages
66
Language
English
Published on
05/09/19
You may also be interested by these reports :
14/11/25
The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its ...
13/11/25
The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...
12/11/25
The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...
10/11/25
The US government has agreed with Novo and Lilly to lower their weight-loss drugs’ prices, mainly in return for a three-year tariff exemption and ...